-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Propagermanium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Focal Segmental Glomerulosclerosis (FSGS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Propagermanium (DMX-200) as an adjunct therapy with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:BND-22 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – propagermanium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry propagermanium Drug Details Propagermanium (DMX-200) as an adjunct therapy with irbesartan is under development...
-
Product Insights
Immunochemistry Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Spot test kits intended generally for rapid diagnosis, with immediate results, through immuno assays. Some of the tests carried out using immunochemistry rapid test include rabies virus test, allergenic food proteins, and enteric infection. The immunochemistry rapid tests and POC pipeline market research report provides comprehensive information about the immunochemistry rapid tests and POC pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Obstructive Pulmonary Disease (COPD) symptoms include inability to completely breathe out air from the lungs leading to shortness of breath. Other symptoms include cough, fatigue, and chest pain. The COPD pipeline drugs market research report provides an analysis of the COPD drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest...